Clinical Trial Update: Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes [NA]

View source ↗

Summary

Completed clinical trial evaluating 18F-APN-1607 PET imaging to assess tau distribution in tauopathy-related parkinsonism syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinsonian Syndromes
• Tauopathy

Drugs mentioned

• APN-1607 (18F) PET tracer (APN-1607)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan | NA | Status: COMPLETED